Man­u­fac­tur­ing roundup: Juno Phar­ma­ceu­ti­cals ac­quires Omega Lab­o­ra­to­ries; Pfiz­er halts dis­tri­b­u­tion of four med­i­cines

Juno Phar­ma­ceu­ti­cals has ac­quired the in­jectable phar­ma­ceu­ti­cal man­u­fac­tur­er Omega Lab­o­ra­to­ries.

The deal gives Juno one of Cana­da’s largest in­jectable man­u­fac­tur­ers, which is ex­pect­ed to trans­form it in­to one of Cana­da’s largest spe­cial­ty gener­ic in­jectable pro­duc­ers with do­mes­tic man­u­fac­tur­ing abil­i­ties.

Juno al­so plans to bring more than 100 new prod­ucts to Cana­da over the next four years, main­ly treat­ments for pain man­age­ment, al­ler­gies, and weight loss. Fi­nan­cial de­tails of the deal were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER